The viral-infection-mediated release of HMGB1 triggers pro-inflammatory responses similar to those of LPS and thus supports the significance of the therapeutic potential of TLR4/MD-2 antagonists for symptom release in viral disease. This evidence concerns the gene HMGB1 and viral infectious disease.